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Background. 
Pulmonary alveolar proteinosis (PAP) is a pulmonary disease characterized by disruption of surfactant ho-
meostasis resulting in its accumulation in the alveoli. PAP is classically classified into three categories (Table 1): 
1/primary (or autoimmune) with antibodies targeting the GM-CSF pathway, 2/secondary to another disease, 
typically a hematologic malignancy, and 3/genetic. 
Case-report. 
A 30 year-old woman received an allogenic hematopoietic stem cell transplantation (HSCT) after treatment for 
acute myeloid leukemia (AML). Within the first 6 months post HSCT, she developed an ocular, oral, digestive and 
hepatic graft-versus-host disease associated with a mixed ventilatory defect with a very severe obstructive 
syndrome and a severe CO diffusion impairment. High resolution computed tomography showed a classical 
“crazy paving” pattern. Aspect and differential cell count of BAL were normal. All microbiological samples 
remained culture negative. Histo-pathological analysis of transbronchial biopsies was unremarkable. Because of 
the severity of the respiratory insufficiency, open-lung biopsy (OBL) could not be performed. Despite multiple 
immunosuppressive therapies, lung function deteriorated rapidly; the patient also developed an excavated fungal 
lesion unresponsive to treatment. She underwent a bilateral lung transplant 48 months after HSCT. Histo- 
pathological analysis of explanted lungs showed obliterative bronchiolitis (OB), diffuse PAP and invasive cavi-
tary pulmonary aspergillosis. 
Conclusions. 
This case illustrates the simultaneous occurrence of OB, PAP and a fungal infection in a 30-year old female 
patient who underwent HSCT for acute myeloid leukemia (AML). To our knowledge this is the only documented 
case of PAP associated with OB treated by lung transplantation.   
1. Introduction 
Pulmonary alveolar proteinosis (PAP) is a pulmonary disease char-
acterized by disruption of surfactant homeostasis resulting in its accu-
mulation in the alveoli, due to abnormalities of either production or 
clearance by alveolar macrophages [1]. 
PAP is classified into three categories: primary (or autoimmune), 
secondary to another disease and genetic. Primary PAP is characterized 
by the existence of auto-antibodies targeting the GM-CSF pathway 
(granulocyte-macrophage colony-stimulating factor) of alveolar 
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macrophages. This affects their surfactant clearance capacity since GM- 
CSF is a growth factor which regulates production and activation of 
macrophages and all granulocytes. Primary PAP is the most common 
form of the disease accounting for more than 90% of PAP cases [2]. 
Secondary PAP is due to surfactant accumulation resulting from alveolar 
macrophage destruction by an external aggression such as a hematologic 
disorder, infection or toxic inhalation [3]. Secondary PAP accounts for 
8–10% [2,4] of all PAP cases and, among secondary PAP, hematological 
disorders are the most frequent cause. Genetic PAP is linked to abnormal 
surfactant production caused by genetic mutations (i.e. SFTPB, SFTPC, 
ABCA3 and TTF1 gene mutations) and is the less common form, typi-
cally occurring in neonates and children [5]. 
Throughout this report we will focus on the form that our patient 
presented: secondary PAP. This is a purely descriptive report of a case 
for which anonymity has been fully preserved and as such, our case- 
report was exempt from approval from an ethics’ board. 
1.1. CASE-REPORT 
A 30 year-old female patient was diagnosed with acute myeloid 
leukemia (AML) in November 2013. Multiple cures of chemotherapy 
(idarubicine, cytarabine, fludarabine and amsacrine) led to a remission. 
In March 2014 (T0) (Fig. 1), because of a high risk of relapse, she 
received an allogenic hematopoietic stem cell transplantation (HSCT). 
At T0 þ 6 months, she developed ocular, oral, digestive and hepatic 
graft-versus-host disease (GVHd). Immunosuppressive therapy by 
tacrolimus, ruxolitinib and oral corticosteroids induced a transient sta-
bilization of GVHd. 
Between T0 þ 6 and T0 þ 12 months, she developed a progressive 
dyspnea, a dry cough and severe asthenia. Pulmonary function tests 
(PFT) showed a mixed ventilatory pattern with a very severe obstructive 
syndrome and severe CO diffusion impairment. Extensive blood analyses 
and non-invasive microbiological samples did not reveal any sign of 
infection. High-resolution computed tomography (HRCT) showed a 
bilateral perihilar mosaicism with zones of ground glass attenuation in a 
“crazy paving” pattern (Fig. 2, panel A). HRCT was completed by Single 
Photon Emission Computed Tomography with a ventilation/perfusion 
phase, which showed that the zones of ground glass attenuation where 
hypoperfused and hypoventilated when compared to adjacent hypo-
dense lung areas. A bronchoscopy with broncho-alveolar lavage (BAL) 
and transbronchial biopsies (TBB) was performed. Differential cell count 
of BAL was normal. All microbiological samples remained culture 
negative. Histo-pathological analysis of lung parenchyma samples was 
unremarkable. Because of the severity of the respiratory insufficiency, a 
surgical lung biopsy was not performed. 
At this stage, our patient presented simultaneously a severe 
obstructive airway disease, potentially attributable to obliterative 
bronchiolitis (OB), and a parenchymal disorder, with a “crazy paving” 
mosaic pattern of ground glass attenuation, for which an infection had 
been reasonably excluded. 
To control the probable OB, immunosuppressive treatment was 
intensified with high-dose oral corticosteroids, and inhaled corticoste-
roids. Macrolides (as immunomodulators) were added and extracorpo-
real photopheresis was implemented. This failed to impact on the 
progression of the airway obstruction and the patient developed a pro-
gressive respiratory failure requiring continuous oxygen therapy and 
subsequently nocturnal non-invasive ventilation. Furthermore, because 
of her immunosuppression, she underwent recurrent hospitalizations for 
IV treatment of lower respiratory tract infections. 
At T0 þ 34 months, indication for a bilateral lung transplant (BLT) 
was confirmed by the local transplant center. At T0 þ 45 months, 
because of worsening of PFT, appearance of a cavitary subpleural lesion 
on HRCT (Fig. 2, panel A (red circle)), and high levels of serum gal-
actomannan, posaconazole was introduced for suspicion of a locally 
invasive pulmonary aspergillosis. 
In spite of several adaptations of anti-fungal therapy, the size of the 
cavitary lesion increased (20 � 24mm with a 4 mm wall). At HSCT þ47 
months, her respiratory condition required continuous high pressure 
non-invasive ventilatory support, and high flow of oxygen. After three 
weeks in the Intensive Care Unit, BLT was performed. 
Macroscopically, the explanted lungs were firm and showed a yellow 
cut surface and a cavity with necrosis (Fig. 2, panel B). 
Microscopic analysis of the explanted lungs (Fig. 2, panel C) revealed 
the presence of 1/obliterative bronchiolitis predominating in the upper 
lobes; 2/diffuse alveolar lipoproteinosis with xanthomatous pneumonia 
and 3/a subpleural cavity with aspergillus fragments (confirmed by 
PCR) without signs of vascular or extrapleural invasion, confirming the 
co-existence of three disorders: OB, PAP and invasive cavitary pulmo-
nary aspergillosis. 
More than two years after BLT, the patient is in good clinical con-
dition, and has normalized her PFT and her lung parenchyma appears 
normal on HRCT. 
2. Discussion 
This case illustrates the simultaneous occurrence of OB, PAP and a 
fungal infection in a 30-year old female patient who underwent HSCT 
Fig. 1. Timeline with CT scan and FEV1 evolution over time.  
Table 1 
Overview of PAP.   
Primary Secondary Genetic 
Etiology Auto-immune (anti-GM- 
CSF Antibody) 
Systemic disease 








Prevalence >90% 8–10% <1% 
Symptoms/ 
signs 
Dry cough, dyspnea, asthenia, variable severity of respiratory failure 
CT-Scan Ground-glass opacities 
and « crazy-paving » 
More diffuse 
ground-glass 
opacities and less 
« crazy-paving » 
pattern 
Ground-glass 
opacities and « 
crazy-paving » 




- GM-CSF subcutaneous 
injections or inhalation 
(in trial) 





- Gene and stem- 
cell therapy 
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after treatment for AML. To our knowledge this is the only documented 
case of PAP associated with OB treated by lung transplantation. 
Secondary PAP represents 8–10% of all cases of PAP, with an inci-
dence and prevalence of approximately 0.05 and 0.5 per million [2], 
respectively. Hematologic disorders account for the majority of these 
cases (75%, mostly myelodysplastic syndromes and AML) [7]. 
Secondary PAP has been reported after bacterial or parasitic infections, 
inhalation of toxic substances such as indium tin oxide [8] (used in the 
fabrication of flat screens), immune deficiency syndromes, 
non-hematological cancers and connective tissue diseases (dermato-
myositis and rheumatoid arthritis) but these descriptions are rare and 
could simply correspond to fortuitous associations [8]. The pathophys-
iology of these secondary PAPs is not well understood. It seems that 
alveolar macrophages are numerically and/or functionally unable to 
ensure clearance of surfactant resulting in bronchial obstruction and 
impaired alveolar gas exchange [3]. By definition, no GM-CSF anti-
bodies are present in secondary PAP as opposed to primary PAP. 
One third of patients with PAP are asymptomatic [8]. PAP symptoms 
are unspecific: progressive dyspnea, dry cough and asthenia. Less 
frequently, fever, hemoptysis and chest pain may occur. Fever seems to 
be more frequent in secondary PAP vs primary PAP (30% versus 1%) 
[9]. Physical examination often shows diffuse fine crackles, signs of 
hypoxemia (cyanosis) and digital clubbing [9]. 
Chest radiography can show symmetric, bilateral, perihilar alveolar 
opacities with the “bat wing” appearance of pulmonary edema but 
without other radiographic signs of left-sided heart failure [10]. HRCT 
typically shows ground-glass opacities, septal reticulations and paren-
chymal consolidation with a ‘‘crazy paving’’ pattern, characteristic of 
PAP [11] although not specific, as this pattern is also associated with 
several other lung diseases [12]. The extent and severity of radiological 
abnormalities usually correlate with the degree of PFT impairment and 
hypoxemia [10]. In a Japanese retrospective cohort study, Ishii et al. 
showed that secondary PAP had a more diffuse radiological presentation 
and that crazy paving attenuation was less common in secondary PAP 
[11]. 
PFTs typically show a restrictive ventilatory defect with severe 
reduction of carbon monoxide diffusing capacity [13]. A low DLCO 
(<44% predicted) in secondary PAP has been associated with poor 
prognosis (survival < 2 years) [4]. 
In about 75% of cases suggestive of PAP, bronchoalveolar-lavage can 
establish the diagnosis [8]. The lavage fluid has a characteristic opaque 
and milky appearance. OLB remains the gold standard for PAP diag-
nosis. However, it is not always required, and can be confusing due to 
false negative results due to sampling error. Microscopic examination of 
biopsies typically shows alveoli filled with granular, eosinophilic ma-
terial that stains with periodic acid–Schiff (PAS), reagent that highlights 
the polysaccharides related to high levels of surfactant proteins [1]. Ishii 
and al. also showed that the overall use of OLB was more common in 
secondary PAP vs. primary PAP (41% versus 7%), probably due to a less 
typical radiological presentation [11]. 
There is no specific treatment for secondary PAP. Therapy for sec-
ondary PAP generally involves treatment of the underlying condition: 
chemotherapy or bone marrow transplantation for hematologic disor-
ders, antimicrobial treatment for infections and avoidance of exposure 
for toxic inhalation. PAP has been described following HSCT [14]; 
however many other reports described a resolution of PAP secondary to 
hematologic malignancy after HSCT [15]. Since the early 1960s, treat-
ment by whole-lung lavage remains the standard of care, without any 
formal validation or comparison to other treatments. 
The prognosis of secondary PAP is much more severe than that of 
autoimmune PAP, with a 2-year survival of 46%, and a median survival 
of 15 months [6] vs a 75% 5 year-survival for primary PAP. Mortality 
results from progression of respiratory failure induced by PAP, second-
ary infections and mortality related to the underlying hematologic dis-
order [6]. 
3. Summary 
Our patient presented a severe form of PAP associated with an OB, 14 
months after HSCT, with characteristic radiological PAP features. BAL 
was not contributive to the diagnosis and surgical lung biopsy was not an 
option due to respiratory limitation. Over a 2-year period, progression of 
Fig. 2. A) Lung CT-scan: “Crazy Paving” pattern with excavated subpleural 
lesion (circled) B) Explanted lung showing diffuse diffuse yellow cut surface 
and the fungal cavity (circled) C) Photomicrograph of pulmonary parenchyma: 
alveoli are filled by eosinophilic amorphous or finely granular material that is 
periodic acid–Schiff-positive. Haematoxylin and eosin stain (x100). (For inter-
pretation of the references to colour in this figure legend, the reader is referred 
to the Web version of this article.) 
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PAP and OB led to severe respiratory failure and BLT. Examination of the 
explanted lung confirmed the presence of 3 distinct lung diseases: OB, 
PAP and an opportunistic fungal infection. The diagnosis of PAP was not 
considered prior to BLT and GM-CSF antibody testing was not per-
formed. However, the clinical presentation is strongly suggestive of 
secondary PAP. More than a year after BLT, the patient has normal PFT 
without any signs of relapse on HRCT. 
This case illustrates the difficulty of diagnosing and managing sec-
ondary PAP, and its progression towards terminal respiratory failure. 
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